Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Patent number: 8790651Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: GrantFiled: June 28, 2012Date of Patent: July 29, 2014Assignee: Zoetis LLCInventors: Gary F. Bammert, Steven A. Dunham
-
Patent number: 8790649Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: October 28, 2011Date of Patent: July 29, 2014Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
-
Publication number: 20140206847Abstract: Provided is a mutant protein capable of binding specifically and quickly to troponin I derived from human myocardium. The mutant protein comprises a first mutant scFv antibody fragment 51 a second mutant scFv antibody fragment 52 and a linker 53. The first mutant scFv antibody fragment 51 comprises a first light chain variable region 51L consisting of an amino acid sequence represented by SEQ ID NO: 76 and a first heavy chain variable region 51H consisting of an amino acid sequence represented by SEQ ID NO: 77. Similarly, the second mutant scFv antibody fragment 52 comprises amino acid sequences of SEQ ID NO: 78 and SEQ ID NO: 79. The linker 53 is provided between the C-terminal of the first heavy chain variable region 51H and the C-terminal of the second heavy chain variable region 52H.Type: ApplicationFiled: January 10, 2014Publication date: July 24, 2014Applicant: PANASONIC CORPORATIONInventor: Takashi ENDOH
-
Patent number: 8785599Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: June 26, 2007Date of Patent: July 22, 2014Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Robyn Gerena
-
Patent number: 8784824Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ? (TNF?) or Tissue Factor protein (which may be truncated).Type: GrantFiled: July 14, 2010Date of Patent: July 22, 2014Assignee: Philogen S.p.A.Inventors: Luciano Zardi, Dario Neri, Barbara Carnemolla, Fredrik Nilsson, Lorenzo Tarli, Laura Borsi, Cornelia Halin
-
Publication number: 20140199317Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.Type: ApplicationFiled: January 24, 2014Publication date: July 17, 2014Applicant: ACCELERON PHARMA, INC.Inventors: Jasbir Seehra, Erik Martinez-Hackert
-
Publication number: 20140199232Abstract: Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.Type: ApplicationFiled: July 16, 2013Publication date: July 17, 2014Applicant: NANODERM SCIENCES, INC.Inventors: Richard A. Winchurch, Roy R. Yeoman
-
Publication number: 20140199242Abstract: Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the MUC4 protein that does not comprise the central tandem repeat (TR) domain of MUC4. Certain antibodies bind to the MUC4 peptide fragment MUC4-?-N-Ter and/or to the MUC4 peptide fragment MUC4-?-C-Ter. Chimeric constructs comprising such antibodies are also provided.Type: ApplicationFiled: June 6, 2012Publication date: July 17, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Surinder K. Batra, Maneesh Jain, Moorthy P. Ponnusamy
-
Publication number: 20140199315Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.Type: ApplicationFiled: November 12, 2013Publication date: July 17, 2014Applicant: Biogen Idec MA Inc.Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff
-
Patent number: 8778699Abstract: A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.Type: GrantFiled: August 4, 2011Date of Patent: July 15, 2014Assignee: Idexx Laboratories, Inc.Inventors: Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
-
Patent number: 8778678Abstract: The composition of activated CD4 cells is derived from a healthy human donor. The composition from the healthy human donor is suspended in an infusion media and packaged in a vehicle for administration to a subject to treat disease.Type: GrantFiled: September 21, 2010Date of Patent: July 15, 2014Assignee: Immunovative Therapies Ltd.Inventor: Michael Har-Noy
-
Publication number: 20140186863Abstract: The present invention relates to a method for detecting a marker for pancreatic disease for obtaining highly reliable results while reducing the risk of complications. It also relates to a method for a detecting a marker for pancreatic disease comprising: measuring the concentration of a marker for pancreatic disease in duodenal juice that is collected from a subject and contains spontaneously discharged pancreatic juice, by a measurement method including detecting antigen or antibody immobilized on a solid phase using an antigen-antibody reaction, and the aforementioned method for detecting a marker for pancreatic disease further including judging the subject to have the possibility of being afflicted with a pancreatic disease in the case the concentration of the marker for pancreatic disease is equal to or greater than a prescribed threshold value.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: OLYMPUS CORPORATIONInventors: Hiromi SANUKI, Nao MORIYA, Rie KATAOKA
-
Patent number: 8765917Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: March 11, 2011Date of Patent: July 1, 2014Assignee: ImmunoGen, Inc.Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
-
Patent number: 8759495Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: GrantFiled: August 11, 2011Date of Patent: June 24, 2014Assignee: Wyeth LLCInventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
-
Patent number: 8759494Abstract: The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 10?10 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof.Type: GrantFiled: September 22, 2010Date of Patent: June 24, 2014Assignee: GEMoaB Monoclonals GmbHInventors: Michael Bachmann, Slava Stamova
-
Publication number: 20140170159Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: March 8, 2013Publication date: June 19, 2014Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
-
Publication number: 20140170684Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.Type: ApplicationFiled: October 3, 2013Publication date: June 19, 2014Applicants: DIVERGENCE, INC., IDEXX LABORATORIES, INC.Inventors: David Allen Elsemore, Laurie A. Flynn, Jinming Geng, Michael Crawford
-
Publication number: 20140166578Abstract: The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.Type: ApplicationFiled: February 20, 2014Publication date: June 19, 2014Applicant: AETHLON MEDICAL, INC.Inventors: Thomas Ichim, Richard H. Tullis
-
Publication number: 20140161810Abstract: The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.Type: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: Aethlon Medical, Inc.Inventors: Thomas Ichim, Richard H. Tullis
-
Publication number: 20140161870Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.Type: ApplicationFiled: July 15, 2013Publication date: June 12, 2014Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
-
Patent number: 8748580Abstract: T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.Type: GrantFiled: March 31, 2011Date of Patent: June 10, 2014Assignee: Immunovative Therapies, Ltd.Inventor: Michael Har-Noy
-
Publication number: 20140155582Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: ApplicationFiled: August 10, 2012Publication date: June 5, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140154715Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.Type: ApplicationFiled: July 6, 2012Publication date: June 5, 2014Applicant: JANSSEN PHARMACEUTICA NVInventors: Marc Hubert Mercken, Marianne Borgers, Marc, Maria, Pierre, Pelagie Vandermeeren, Bianca Julia J Van Broeck
-
Publication number: 20140154249Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.Type: ApplicationFiled: February 12, 2014Publication date: June 5, 2014Applicant: Biokine Therapeutics Ltd.Inventors: Michal ABRAHAM, Orly Eizenberg, Amnon Peled
-
Patent number: 8742076Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.Type: GrantFiled: January 16, 2009Date of Patent: June 3, 2014Assignee: Genentech, Inc.Inventors: Robert L. Cohen, Edward HyungSuk Ha, Mark E. Reynolds
-
Patent number: 8741289Abstract: Novel antibodies and antigen binding fragments that specifically binds to S?glec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of S?glec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of S?glec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: October 6, 2010Date of Patent: June 3, 2014Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Patent number: 8741615Abstract: A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R1 is alkyl, aryl, carboxyl, or amino; n is an integer from 5 to 1000; and m is an integer from 1 to 10.Type: GrantFiled: August 30, 2012Date of Patent: June 3, 2014Assignee: Industrial Technology Research InstituteInventors: Wen-Hsiang Chang, Wen-Uan Hsieh, Shiu-Hua Huang, Chin-I Lin, Shian-Jy Jassy Wang, Kelly Teng
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Patent number: 8734801Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8735546Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: GrantFiled: August 2, 2011Date of Patent: May 27, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20140140933Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: ApplicationFiled: November 1, 2013Publication date: May 22, 2014Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Publication number: 20140141486Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: ApplicationFiled: January 24, 2014Publication date: May 22, 2014Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Publication number: 20140141485Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: December 23, 2013Publication date: May 22, 2014Applicant: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Publication number: 20140141022Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
-
Publication number: 20140135484Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: November 22, 2013Publication date: May 15, 2014Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20140135476Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: January 27, 2014Publication date: May 15, 2014Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: MARTIN HALL, STURE LARSSON, ANDREAS MURANYI, GUSTAV RODRIGO, JINYU ZOU, PER-MIKAEL ABERG
-
Patent number: 8722855Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: October 28, 2010Date of Patent: May 13, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8722047Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.Type: GrantFiled: April 5, 2010Date of Patent: May 13, 2014Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Publication number: 20140124448Abstract: The present invention provides an immunoaffinity separation material, comprising an antibody derivative having high specificity for soluble and cell bound IgE, an apheresis device comprising said material and its use for apheresis, specifically for plasmapheresis. It further provides a recombinant single chain antibody fragment with high specificity for soluble and cell bound IgE that is free of any tag sequences as well as the method for its production.Type: ApplicationFiled: April 13, 2012Publication date: May 8, 2014Inventors: Hans Huber, Christian Lupinek, Bernhard Maderegger, Gottfried Stegfellner, Rudolf Valenta, Josef Boeckmann, Friedrich Dorner, Wolfgang Schallenberger
-
Publication number: 20140127779Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Patent number: 8716031Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.Type: GrantFiled: May 12, 2009Date of Patent: May 6, 2014Assignees: RIKEN, Animal Allergy Clinical LaboratoriesInventors: Kenichi Masuda, Yasuyuki Ishii, Nobutaka Yasuda
-
Patent number: 8716450Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: October 15, 2010Date of Patent: May 6, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Rajesh V. Kamath, Junian Liu, Marie P. Honore
-
Patent number: 8716455Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: August 25, 2008Date of Patent: May 6, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20140121351Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Stefan Haider, Andreas Ivens, Hanspeter Rottensteiner, Juregen Siekmann, Peter Turecek
-
Publication number: 20140120117Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Publication number: 20140120118Abstract: A compound which is selected from A: B: and C: and salts and solvates thereof, as well as conjugates thereof with cell binding agent.Type: ApplicationFiled: October 11, 2013Publication date: May 1, 2014Applicant: Spirogen SàrlInventor: Philip Wilson HOWARD
-
Publication number: 20140120617Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.Type: ApplicationFiled: June 26, 2013Publication date: May 1, 2014Inventors: JACQUES F. BANCHEREAU, SANGKON OH, GERARD ZURAWSKI, SANDRA ZURAWSKI, DAPENG LI
-
Publication number: 20140113385Abstract: Disclosed are compositions and methods for identifying and preferably quantifying single antigens/molecules in tissue sections and other cell preparations. The methods make use of specific antibodies or aptomers linked with beads or other micro-particles using bright field microscopy having the purpose to identify and quantify single antigens or other molecules.Type: ApplicationFiled: October 21, 2011Publication date: April 24, 2014Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventor: Clive R. Taylor
-
Publication number: 20140112925Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.Type: ApplicationFiled: March 26, 2012Publication date: April 24, 2014Applicant: UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNVERSITIAT MAINZInventors: Ralf-Holger Voss, Shao-An Xue, Matthias Theobald, Hans Stauss